• 제목/요약/키워드: bone marrow transplantation

검색결과 181건 처리시간 0.033초

재생불량성 빈혈 환자의 편평상피세포암 (SQUAMOUS CELL CARCINOMA WITH APLASTIC ANEMIA PATIENT)

  • 이계영;민경인;이주현;김철환
    • Journal of the Korean Association of Oral and Maxillofacial Surgeons
    • /
    • 제27권1호
    • /
    • pp.65-68
    • /
    • 2001
  • The major manifestations of aplastic anemia are characterized by persistent bone marrow aplasia and peripheral pancytopenia due to defective stem cells in which differentiation is not curtailed or preferential elimination of stem cells with self-renewal capacity, which results in serious complications such as bleeding and infection. Recent advances in the therapeutic modalities, such as bone marrow transplantation and immunosuppressive therapy, and in supportive measures as component transfusion and infection control with better quality of antibiotics resulted in an improved survival and subsequently increased possibility of complications which need surgical intervention. Considering the fact that surgery may not only control complications, but offers the opportunity to give effective therapy for aplastic anemia and therefore improves chances for survival, it is strongly suggested that active surgical intervention should be performed. We report a case of patient with aplastic anemia who had been performed surgical intervention of partial maxillectomy for the squamous cell carcinoma on maxilla without serious complications during perioperative and postoperative period.

  • PDF

Clinical Outcomes of Lung Transplantation: Experience at Asan Medical Center

  • Jeong, Yong Ho;Choi, Sehoon;Park, Seung-Il;Kim, Dong Kwan;Asan Medical Center Lung Transplantation Team
    • Journal of Chest Surgery
    • /
    • 제51권1호
    • /
    • pp.22-28
    • /
    • 2018
  • Background: Lung transplantation is a life-saving procedure in patients with end-stage lung disease, and is increasingly performed in Korea. Methods: We retrospectively evaluated the outcomes of patients who received a lung transplant at Asan Medical Center between January 2008 and December 2016. Thirteen of 54 patients experienced multiorgan transplantation; the remaining 41 who received only lung grafts were included. Results: The mean age of the lung transplant recipients was 44.6 years; 27 were men and 14 were women. The most frequent reasons were idiopathic interstitial pneumonia (21 of 41 patients, 51.2%), interstitial lung disease (9 of 41, 22.0%), and bronchiolitis obliterans after bone marrow transplantation (7 of 41, 17.1%). The median waiting time was 47 days, and many patients received preoperative intensive care (27 of 41, 65.9%), ventilator support (26 of 41, 63.4%), or extracorporeal life support (19 of 41, 46.3%). All 41 patients received bilateral lung grafts. Ten deaths occurred (24.3%), including 5 cases of early mortality (12.2%) and 5 cases of late mortality (12.2%). The 1-, 3-, and 5-year survival rates were 78.9%, 74.2%, and 69.3%, respectively. Conclusion: Despite a high percentage of patients who required preoperative intensive care, the transplantation outcomes were acceptable.

Olig2-expressing Mesenchymal Stem Cells Enhance Functional Recovery after Contusive Spinal Cord Injury

  • Park, Hwan-Woo;Oh, Soonyi;Lee, Kyung Hee;Lee, Bae Hwan;Chang, Mi-Sook
    • International Journal of Stem Cells
    • /
    • 제11권2호
    • /
    • pp.177-186
    • /
    • 2018
  • Background and Objectives: Glial scarring and inflammation after spinal cord injury (SCI) interfere with neural regeneration and functional recovery due to the inhibitory microenvironment of the injured spinal cord. Stem cell transplantation can improve functional recovery in experimental models of SCI, but many obstacles to clinical application remain due to concerns regarding the effectiveness and safety of stem cell transplantation for SCI patients. In this study, we investigated the effects of transplantation of human mesenchymal stem cells (hMSCs) that were genetically modified to express Olig2 in a rat model of SCI. Methods: Bone marrow-derived hMSCs were genetically modified to express Olig2 and transplanted one week after the induction of contusive SCI in a rat model. Spinal cords were harvested 7 weeks after transplantation. Results: Transplantation of Olig2-expressing hMSCs significantly improved functional recovery in a rat model of contusive SCI model compared to the control hMSC-transplanted group. Transplantation of Olig2-expressing hMSCs also attenuated glial scar formation in spinal cord lesions. Immunohistochemical analysis showed that transplanted Olig2-expressing hMSCs were partially differentiated into Olig1-positive oligodendrocyte-like cells in spinal cords. Furthermore, NF-M-positive axons were more abundant in the Olig2-expressing hMSC-transplanted group than in the control hMSC-transplanted group. Conclusions: We suggest that Olig2-expressing hMSCs are a safe and optimal cell source for treating SCI.

조혈모세포이식 후 생존기간에 따른 수행능력과 삶의 질 (Performance Status and Quality Life of Patients with Hematopoietic Stem Cell Transplantation According to Period of Survival)

  • 우혜덕;박정숙
    • 종양간호연구
    • /
    • 제12권2호
    • /
    • pp.132-138
    • /
    • 2012
  • Purpose: The purpose of this study was to identify the performance status and quality of life (QOL) of patients after hematopoietic stem cell transplantation (HSCT) according to period of survival. Methods: Participants consists of 83 HSCT patients who were being treated regularly at out-patient clinic in two general hospitals in D city. Data were collected using questionnaires that were modified by Functional Assessment of Cancer Therapy-Bone Marrow Transplabtation (FACT-BMT) scale and Eastern Cooperative Oncology Group (ECOG). Results: The unrelated HSCT group's survival period was significantly worse than related HSCT group and autologous HSCT group. Performance status of the group with more than 3 years survival was significantly higher than that of the group with less than a year survival. The mean score of total QOL of HSCT patients was 2.69 out of 4. Total QOL was not significantly different among period of survival less than 1 year, 1-3 years, and more than 3 years. But BMT QOL was shown that the group with more than 3 years survival was higher than the groups with less than a year survival. Conclusion: Performance status and BMT QOL of the group with less than 1 year survival was significantly lowered than the groups with more than 3 years survival.

Hematopoietic stem cell transplantation in children with acute leukemia: similar outcomes in recipients of umbilical cord blood versus marrow or peripheral blood stem cells from related or unrelated donors

  • Yi, Eun-Sang;Lee, Soo-Hyun;Son, Meong-Hi;Kim, Ju-Youn;Cho, Eun-Joo;Lim, Su-Jin;Cheuh, Hee-Won;Yoo, Keon-Hee;Sung, Ki-Woong;Koo, Hong-Hoe
    • Clinical and Experimental Pediatrics
    • /
    • 제55권3호
    • /
    • pp.93-99
    • /
    • 2012
  • Purpose: This study compared outcomes in children with acute leukemia who underwent transplantations with umbilical cord blood (UCB), bone marrow, or peripheral blood stem cells from a human leukocyte antigen (HLA)-matched related donor (MRD) or an unrelated donor (URD). Methods: This retrospective study included consecutive acute leukemia patients who underwent their first allogeneic hematopoietic stem cell transplantation (HSCT) at Samsung Medical Center between 2005 and 2010. Patients received stem cells from MRD (n=33), URD (n=46), or UCB (n=41). Results: Neutrophil and platelet recovery were significantly longer after HSCT with UCB than with MRD or URD ($p$ <0.01 for both). In multivariate analysis using the MRD group as a reference, the URD group had a significantly higher risk of grade III to IV acute graft-versus-host disease (GVHD; relative risk [RR], 15.2; 95% confidence interval [CI], 1.2 to 186.2; $p$=0.03) and extensive chronic GVHD (RR, 6.9; 95% CI, 1.9 to 25.2; $p$ <0.01). For all 3 donor types, 5-year event-free survival (EFS) and overall survival were similar. Extensive chronic GVHD was associated with fewer relapses (RR, 0.1; 95% CI, 0.04 to 0.6; $p$ <0.01). Multivariate analysis showed that lower EFS was associated with advanced disease at transplantation (RR, 3.2; 95% CI, 1.3 to 7.8; $p$ <0.01) and total body irradiation (RR, 2.1; 95% CI, 1.0 to 4.3; $p$=0.04). Conclusion: Survival after UCB transplantation was similar to survival after MRD and URD transplantation. For patients lacking an HLA matched donor, the use of UCB is a suitable alternative.

혈관생성 억제제를 주사한 마우스 모델에서의 골수 세포의 복강 내 주입 후 생착 (Engraftment of Intraperitoneally Injected Bone Marrow Cells to Newborn Mice Injected with an Angiogenesis Inhibitor)

  • 조수진;주선영;우소연;강형진;안효섭;유경하;박은애
    • Neonatal Medicine
    • /
    • 제15권1호
    • /
    • pp.22-31
    • /
    • 2008
  • 목 적 : 기관지폐이형성증은 미숙한 폐에서의 혈관과 폐포발달의 저해로 특징 질 수 있다. 폐 발달의 결과를 고려하면 줄기세포의 투여로 자가 회복기전을 이용한 폐 발달의 촉진의 가능성은 유망하고 이로 폐 기관지이 형성의 유병률과 합병증을 줄일 수 있다. 강화된 Green fluorescent protein (EGFP)를 표기인자로 표시한 줄기세포를 비 EGFP 마우스에 주사하여 생착 여부를 보고자 하였다. 방 법 : VEGFR2 억제제인 SU1498을 생후 3일된 마우스에 주사하여 폐포발달이 저해된 모형을 만들었다. 생후 4일에 $1{\times}10^6$ EGFP 양성 줄기세포를 복강 내로 주입하였다. 줄기세포를 투여한 폐의 형태학적인 분석과 면역염색을 시행 하였고, 주입된 줄기 세포의 생착을 확인하기 위해서 동일초점 현미경으로 분석하였다. 결 과 : SU1498을 주사한 신생마우스에서 폐포 표면적과 평균 폐포 용적이 감소되었다. 폐 발달이 억제된 마우스 모형에서 주입한 EGFP 양성 줄기세포가 발견 되었고, 내피세포와 외피세포로 분화함을 공초점 현미경으로 확인하였다. 결 론 : 주입된 EGFP 양성 줄기세포가 혈관생성억제제를 이용하여 만든 마우스의 폐 발달 저해 모형에서 생착 하여 내피세포와 외피세포로 분화함을 확인하였다.

동종골수이식 후 폐합병증 (Lung Complications After Allogenic Bone Marrow Transplantaion)

  • 제갈양진;이제환;이규형;김우건;심태선;임채만;고윤석;이상도;김우성;김원동;김동순
    • Tuberculosis and Respiratory Diseases
    • /
    • 제49권2호
    • /
    • pp.207-216
    • /
    • 2000
  • 연구배경 : 동종골수이식은 난치성 혈액질환의 효과적인 치료법이나 약 40%에서 치료와 관련된 합병증으로 사망하고, 그중 10-40%가 폐합병증이 주된 사인이므로 폐합병증의 발생유무는 동종골수이식 치료성적에 중요한 영향을 미친다. 국내에서는 이식편대숙주질환이 서구보다 적고 CMV감염률이 높아 폐합병중이 서구와는 다른 양상으로 나타나리라 사료되어 국내에서 동종 골수이식 후 발생한 폐합병증의 임상양상을 알아보고자 본 연구를 시행하였다. 방법 : 1993년 12월부터 1999년 5월까지 서울중앙병원에서 동종골수이식을 시행한 100명의 성인환자를 대상으로 후향적 코호트법으로 연구하였다. 패합병증은 발생시기에 따라 골수가 생착하는 시기인 30일 전후로 나누고 다시 병인에 따라 감염성 혹은 비감염성으로 분류하였다. 감염성 합병증은 혈액이나 BAL액, 흉막액, 객담검사등에서 병원체가 증명된 경우에서나 임상적으로 감염성 합병증이 의심되는 경우에서 항균제 혹은 항진균제를 사용하여 임상적, 방사선학적 호전이 있는 경우로 정의하였다. 결과 : 1) 폐합병증은 100명중 54명에서 83건이 발생하였다. 2) 30일 이전에는 비감염성 합병증이, 30일 이후에는 감염성 합병증이 더 많이 발생 하였고, 기저질환이 재발되거나 만성 이식편대숙주질환이 없으면 1년 이후에는 감염성 합병증은 발생하지 않았다. 3) 비감염성 합병증으로는 흉막액이 27건으로 가장 많았고, 그 외 비감염성 합병증으로는 폐부종 8건, 미만성 폐포출혈 1 건, BO 2건, BOOP 1건이 있었다. 4) 감염성 합병증은 세균성 폐렴 9 건, 바이러스성 폐렴 4건, 폐결핵 3건, PCP 1건, 진균성 폐렴 5건, 결핵성 흉막염 3건이 있었다. 5) CMV감염과 호중구 회복지연은 폐합병증과 관련된 위험인자로 확인되었다. 6) 폐합병증이 발생한 경우 동종골수이식 후 사망률이 유의하게 높았다. 결론 : 동종골수이식 후 폐합병증은 54%에서 발생하였고, 폐합병증이 발생한 경우에 이식 후 사망률이 증가하였다.

  • PDF

가토의 상악동 골이식술시 미분화 간엽 줄기세포의 골형성 효과 (THE EFFECTS OF UNDIFFERENTIATED MESENCHYMAL STEM CELLS ON SINUS BONE GRAFTING IN RABBIT)

  • 오승환;채영원;김범수;여인범;조필귀
    • Maxillofacial Plastic and Reconstructive Surgery
    • /
    • 제28권6호
    • /
    • pp.520-530
    • /
    • 2006
  • Undifferentiated mesencymal stem cells(UMSCs) have been thought to be multipotent cells that can replicate as undifferentiated cells and that have the potential to differentiate into lineages of mesenchymal tissue including the bone, cartilage, fat, tendon, muscle, and marrow stroma. It can be used to sinus lifting, Guided bone regeneration, other bone graft in dental part. The purpose of this study is to evaluate the effect of mesencymal stem cells on sinus augmentation with autogenous bone, fibrin glue mixture in a rabbit model. 8 New Zealand white rabbits were divided randomly into 4 groups based on their time of sacrifice(1, 2, 4 and 8 weeks). First, undifferentiated mesenchymal stem cells were isolated from iliac crest marrow of rabbits and expanded in vitro. cell culture was performed in accordance with the technique described by Tsutsumi et al. In the present study, The animals were sacrificed at 1, 2, 4 and 8 weeks after transplantation, and the bone formation ability of each sides was evaluated clinically, radiologically, histologically and histomorphologically. According to the histological observations, Stem cell group showed integrated graft bone with host bone from sinus wall. At 2 and 4weeks, It showed active newly formed bone and neovascularization. At 8 weeks, lamella bone was observed in sinus graft material area. Radiologically, autobone with stem cell showed more radiopaque than autobone without stemcell. there were significant differences in bone volume between 2 and 4 weeks (p<0.05). In summary, the autobone with stem cells had well-formed, newly formed bone and neovasculization, compared with the autobone without stem cells (esp. 2 weeks and 4 weeks) The findings of this experimental study indicate that the use of a mixture of mesenchymal stem cell yielded good results in osteogenesis and bone volume comparable with that achieved by autogenous bone. Therefore, this application of this promising new sinus floor elevation method for implants with tissue engineering technology deserves further study.

Diagnosis of Graft-Versus-Host Disease after Bone Marrow Transplantation by in vivo Proton MR Spectroscopy of the Liver: Correlation with Pathologic Results

  • Cho, Soon-Gu;Lee, Moon-Hee;Suh, Chang-Hae
    • 대한자기공명의과학회:학술대회논문집
    • /
    • 대한자기공명의과학회 2001년도 제6차 학술대회 초록집
    • /
    • pp.135-135
    • /
    • 2001
  • Purpose: To know the differences of the proton MR spectroscopic features of the liver between th patients with graft-versus-host disease (GVHD) and without GVHD (non-GVHD) after to marrow transplantation (BMT), and to evaluate the possibility to discriminate GVHD fro non-GVHD by analysis of the in vivo proton MR spectra. Method: We evaluated the in vivo proton MR spectra from the livers of 37 patients wh underwent BMT. Our series included 14 cases with GVHD and 23 without GVHD in the liver. Nineteen men and 18 women were included in our series. All cases of GVHD and 2 o non-GVHD were confirmed by liver biopsy and remaining of non-GVHD by evaluation clinical follow up. Proton MR spectroscopy (1H-MRS) was performed at 1.5T GE Sign Horizon (GE Medical System, Milwaukee, USA) system using localized proton STEAM sequence and body coil in all cases with subjects were located in supine position. N respiratory interruption was required during the spectroscopic signal acquisition. Paramete using in MRS were: TR = over 3000ms, TE = 30ms, number of scans = 128, voxel size = ($2{\times}2{\times}2$)$cm^3$, and one NEX. We evaluated the spectra with an attention to the differences o patterns of the peaks between GVHD and non-GVHD groups. The ratio of peak area of peaks at 1.6-4.1ppm to lipid (0.9-1.6ppm) [P(1.6-4.1ppm)/P(0.9-1.6ppm)] was calculated in GVHD and non-GVHD group, and compared the results between these groups. We als evaluated the sensitivity and specificity for discriminating GVHD from non-GVHD by anal of 1H-MRS.

  • PDF

Fertility preservation for patients with hematologic malignancies: The Korean Society for Fertility Preservation clinical guidelines

  • Lee, Dong-Yun;Kim, Seul Ki;Kim, Miran;Hwang, Kyung Joo;Kim, Seok Hyun
    • Clinical and Experimental Reproductive Medicine
    • /
    • 제44권4호
    • /
    • pp.187-192
    • /
    • 2017
  • Although the survival rate of hematologic malignancies in young patients is very high, cytotoxic therapies such as chemotherapy and total body irradiation therapy can significantly reduce a patient's reproductive capacity and cause irreversible infertility. Early ovarian failure also commonly occurs following additional cancer treatment, bone marrow transplantation, or autologous transplantation. Because the risk of early ovarian failure depends on the patient's circumstances, patients with a hematologic malignancy must consult health professionals regarding fertility preservation before undergoing treatments that can potentially damage their ovaries. While it is widely known that early menopause commonly occurs following breast cancer treatment, there is a lack of reliable study results regarding fertility preservation during hematologic malignancy treatment. Therefore, an in-depth discussion between patients and health professionals about the pros and cons of the various options for fertility preservation is necessary. In this study, we review germ cell toxicity, which occurs during the treatment of hematologic malignancies, and propose guidelines for fertility preservation in younger patients with hematologic malignancies.